Jacobi Capital Management LLC Has $2.92 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Jacobi Capital Management LLC grew its position in shares of Amgen Inc. (NASDAQ:AMGN) by 4.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,208 shares of the medical research company’s stock after acquiring an additional 463 shares during the quarter. Jacobi Capital Management LLC’s holdings in Amgen were worth $2,921,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Lansing Street Advisors increased its holdings in shares of Amgen by 1.3% during the third quarter. Lansing Street Advisors now owns 2,582 shares of the medical research company’s stock valued at $832,000 after acquiring an additional 32 shares in the last quarter. Unionview LLC increased its holdings in shares of Amgen by 3.8% during the third quarter. Unionview LLC now owns 876 shares of the medical research company’s stock valued at $282,000 after acquiring an additional 32 shares in the last quarter. AM Investment Strategies LLC increased its holdings in shares of Amgen by 0.4% during the third quarter. AM Investment Strategies LLC now owns 7,471 shares of the medical research company’s stock valued at $2,407,000 after acquiring an additional 33 shares in the last quarter. Avidian Wealth Enterprises LLC increased its holdings in shares of Amgen by 0.6% during the third quarter. Avidian Wealth Enterprises LLC now owns 5,863 shares of the medical research company’s stock valued at $1,889,000 after acquiring an additional 33 shares in the last quarter. Finally, Beacon Financial Advisory LLC increased its holdings in shares of Amgen by 4.6% during the third quarter. Beacon Financial Advisory LLC now owns 769 shares of the medical research company’s stock valued at $248,000 after acquiring an additional 34 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Jonathan P. Graham sold 25,045 shares of the company’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at approximately $8,496,669.44. This represents a 46.35 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares of the company’s stock, valued at $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 69,341 shares of company stock worth $20,644,335 in the last ninety days. 0.69% of the stock is currently owned by insiders.

Amgen Stock Performance

NASDAQ:AMGN opened at $308.06 on Friday. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The firm has a market cap of $165.49 billion, a price-to-earnings ratio of 40.80, a PEG ratio of 2.63 and a beta of 0.56. The business’s fifty day moving average is $280.87 and its 200 day moving average is $300.16.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a $2.38 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a yield of 3.09%. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio is currently 126.09%.

Analyst Ratings Changes

AMGN has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft cut their target price on Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Redburn Partners cut their target price on Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. William Blair reaffirmed an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Amgen in a research report on Wednesday, February 5th. Finally, StockNews.com cut Amgen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $314.09.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.